The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma.
ERJ Open Res
; 7(4)2021 Oct.
Article
em En
| MEDLINE
| ID: mdl-34853785
ABSTRACT
BACKGROUND:
Asthma is the most common chronic disease in children, many of whom are managed solely with a short-acting ß2-agonist (SABA). In adults, the evidence that budesonide-formoterol as sole reliever therapy markedly reduces the risk of severe exacerbations compared with SABA alone has contributed to the Global Initiative for Asthma recommending against SABA monotherapy in this population. The current lack of evidence in children means it is unknown whether these findings are also relevant to this demographic. High-quality randomised controlled trials (RCTs) are needed.OBJECTIVE:
The aim of this study is to determine the efficacy and safety of as-needed budesonide-formoterol therapy compared with as-needed salbutamol in children aged 5 to 15â years with mild asthma, who only use a SABA.METHODS:
A 52-week, open-label, parallel group, phase III RCT will recruit 380 children aged 5 to 15â years with mild asthma. Participants will be randomised 11 to either budesonide-formoterol (Symbicort Rapihaler®) 50/3â µg, two actuations as needed, or salbutamol (Ventolin®) 100 â µg, two actuations as needed. The primary outcome is asthma attacks as rate per participant per year. Secondary outcomes assess asthma control, lung function, exhaled nitric oxide and treatment step change. A cost-effectiveness analysis is also planned.CONCLUSION:
This is the first RCT to assess the safety and efficacy of as-needed budesonide-formoterol in children with mild asthma. The results will provide a much-needed evidence base for the treatment of mild asthma in children.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article